BRIEF-Mirum Pharmaceuticals Enters Into Definitive Agreement To Acquire Bluejay Therapeutics

Reuters12-08

BRIEF-Mirum Pharmaceuticals Enters Into Definitive Agreement To Acquire Bluejay <a href="https://laohu8.com/S/LENZ">Therapeutics</a>

Dec 8 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O:

MIRUM PHARMACEUTICALS: DEAL APPROVED BY BOARDS OF BOTH COS AND EXPECTED TO CLOSE IN Q1 2026
MIRUM PHARMACEUTICALS ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE BLUEJAY THERAPEUTICS
MIRUM PHARMACEUTICALS: ENTERED INTO DEFINITIVE AGREEMENT WITH SYNDICATE OF HEALTHCARE INVESTORS FOR A PRIVATE PLACEMENT
MIRUM PHARMACEUTICALS: TO BUY BLUEJAY FOR $250 MILLION IN CASH, $370 MILLION IN CO'S COMMON STOCK & SALES-BASED MILESTONE PAYMENTS OF UPTO $200 MILLION IN CASH
MIRUM PHARMACEUTICALS: AZURE PHASE 3 PROGRAM CURRENTLY ENROLLING PATIENTS, WITH TOP-LINE DATA EXPECTED IN 2H 2026 WITH BLA SUBMISSION, LAUNCH IN 2027
MIRUM PHARMACEUTICALS: PRIVATE PLACEMENT EXPECTED TO CLOSE CONCURRENTLY WITH ACQUISITION & RESULT IN GROSS PROCEEDS TO CO OF ABOUT $200 MILLION
MIRUM PHARMACEUTICALS: BRELOVITUG BEING EVALUATED IN AZURE PHASE 3 REGISTRATIONAL PROGRAM FOR HDV

Further company coverage: MIRM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589355362?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589355362","market":"fut","top_or_hot":-1,"title":"BRIEF-Mirum Pharmaceuticals Enters Into Definitive Agreement To Acquire Bluejay Therapeutics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Mirum Pharmaceuticals Enters Into Definitive Agreement To Acquire Bluejay <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></title></head><body><p><span>Dec 8 (Reuters)</span><span> - </span>Mirum Pharmaceuticals Inc <span>MIRM.O</span>:</p><ul><li><p>MIRUM PHARMACEUTICALS: DEAL APPROVED BY BOARDS OF BOTH COS AND EXPECTED TO CLOSE IN Q1 2026</p></li><li><p>MIRUM PHARMACEUTICALS ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE BLUEJAY THERAPEUTICS</p></li><li><p>MIRUM PHARMACEUTICALS: ENTERED INTO DEFINITIVE AGREEMENT WITH SYNDICATE OF HEALTHCARE INVESTORS FOR A PRIVATE PLACEMENT</p></li><li><p>MIRUM PHARMACEUTICALS: TO BUY BLUEJAY FOR $250 MILLION IN CASH, $370 MILLION IN CO'S COMMON STOCK &amp; SALES-BASED MILESTONE PAYMENTS OF UPTO $200 MILLION IN CASH</p></li><li><p>MIRUM PHARMACEUTICALS: AZURE PHASE 3 PROGRAM CURRENTLY ENROLLING PATIENTS, WITH TOP-LINE DATA EXPECTED IN 2H 2026 WITH BLA SUBMISSION, LAUNCH IN 2027</p></li><li><p>MIRUM PHARMACEUTICALS: PRIVATE PLACEMENT EXPECTED TO CLOSE CONCURRENTLY WITH ACQUISITION &amp; RESULT IN GROSS PROCEEDS TO CO OF ABOUT $200 MILLION</p></li><li><p>MIRUM PHARMACEUTICALS: BRELOVITUG BEING EVALUATED IN AZURE PHASE 3 REGISTRATIONAL PROGRAM FOR HDV</p></li></ul><p>Further company coverage: <span>MIRM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Mirum Pharmaceuticals Enters Into Definitive Agreement To Acquire Bluejay Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Mirum Pharmaceuticals Enters Into Definitive Agreement To Acquire Bluejay Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Mirum Pharmaceuticals Enters Into Definitive Agreement To Acquire Bluejay <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></title></head><body><p><span>Dec 8 (Reuters)</span><span> - </span>Mirum Pharmaceuticals Inc <span>MIRM.O</span>:</p><ul><li><p>MIRUM PHARMACEUTICALS: DEAL APPROVED BY BOARDS OF BOTH COS AND EXPECTED TO CLOSE IN Q1 2026</p></li><li><p>MIRUM PHARMACEUTICALS ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE BLUEJAY THERAPEUTICS</p></li><li><p>MIRUM PHARMACEUTICALS: ENTERED INTO DEFINITIVE AGREEMENT WITH SYNDICATE OF HEALTHCARE INVESTORS FOR A PRIVATE PLACEMENT</p></li><li><p>MIRUM PHARMACEUTICALS: TO BUY BLUEJAY FOR $250 MILLION IN CASH, $370 MILLION IN CO'S COMMON STOCK &amp; SALES-BASED MILESTONE PAYMENTS OF UPTO $200 MILLION IN CASH</p></li><li><p>MIRUM PHARMACEUTICALS: AZURE PHASE 3 PROGRAM CURRENTLY ENROLLING PATIENTS, WITH TOP-LINE DATA EXPECTED IN 2H 2026 WITH BLA SUBMISSION, LAUNCH IN 2027</p></li><li><p>MIRUM PHARMACEUTICALS: PRIVATE PLACEMENT EXPECTED TO CLOSE CONCURRENTLY WITH ACQUISITION &amp; RESULT IN GROSS PROCEEDS TO CO OF ABOUT $200 MILLION</p></li><li><p>MIRUM PHARMACEUTICALS: BRELOVITUG BEING EVALUATED IN AZURE PHASE 3 REGISTRATIONAL PROGRAM FOR HDV</p></li></ul><p>Further company coverage: <span>MIRM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MIRM","symbol_name":"Mirum Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nP8N3W4067:1","article_id":"2589355362","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589355362","pubTimestamp":1765198807,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Mirum Pharmaceuticals Enters Into Definitive Agreement To Acquire Bluejay TherapeuticsDec 8  - Mirum Pharmaceuticals Inc MIRM.O:MIRUM PHARMACEUTICALS: DEAL APPROVED BY BOARDS OF BOTH COS AND EXPECTED TO CLOSE IN Q1 2026MIRUM PHARMACEUTICALS ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE BLUEJAY THERAPEUTICSMIRUM PHARMACEUTICALS: ENTERED INTO DEFINITIVE AGREEMENT WITH SYNDICATE OF HEALTHCARE INVESTORS FOR A PRIVATE PLACEMENTMIRUM PHARMACEUTICALS: TO BUY BLUEJAY FOR $250 MILLION IN CASH, $370 MILLION IN CO'S COMMON STOCK & SALES-BASED MILESTONE PAYMENTS OF UPTO $200 MILLION IN CASHMIRUM PHARMACEUTICALS: AZURE PHASE 3 PROGRAM CURRENTLY ENROLLING PATIENTS, WITH TOP-LINE DATA EXPECTED IN 2H 2026 WITH BLA SUBMISSION, LAUNCH IN 2027MIRUM PHARMACEUTICALS: PRIVATE PLACEMENT EXPECTED TO CLOSE CONCURRENTLY WITH ACQUISITION & RESULT IN GROSS PROCEEDS TO CO OF ABOUT $200 MILLIONMIRUM PHARMACEUTICALS: BRELOVITUG BEING EVALUATED IN AZURE PHASE 3 REGISTRATIONAL PROGRAM FOR HDVFurther company covera","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MIRM":"Mirum Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"简介-Mirum Pharmaceuticals签订收购Bluejay Therapeutics的最终协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRM":0.9},"content_text":"BRIEF-Mirum Pharmaceuticals Enters Into Definitive Agreement To Acquire Bluejay TherapeuticsDec 8 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O:MIRUM PHARMACEUTICALS: DEAL APPROVED BY BOARDS OF BOTH COS AND EXPECTED TO CLOSE IN Q1 2026MIRUM PHARMACEUTICALS ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE BLUEJAY THERAPEUTICSMIRUM PHARMACEUTICALS: ENTERED INTO DEFINITIVE AGREEMENT WITH SYNDICATE OF HEALTHCARE INVESTORS FOR A PRIVATE PLACEMENTMIRUM PHARMACEUTICALS: TO BUY BLUEJAY FOR $250 MILLION IN CASH, $370 MILLION IN CO'S COMMON STOCK & SALES-BASED MILESTONE PAYMENTS OF UPTO $200 MILLION IN CASHMIRUM PHARMACEUTICALS: AZURE PHASE 3 PROGRAM CURRENTLY ENROLLING PATIENTS, WITH TOP-LINE DATA EXPECTED IN 2H 2026 WITH BLA SUBMISSION, LAUNCH IN 2027MIRUM PHARMACEUTICALS: PRIVATE PLACEMENT EXPECTED TO CLOSE CONCURRENTLY WITH ACQUISITION & RESULT IN GROSS PROCEEDS TO CO OF ABOUT $200 MILLIONMIRUM PHARMACEUTICALS: BRELOVITUG BEING EVALUATED IN AZURE PHASE 3 REGISTRATIONAL PROGRAM FOR HDVFurther company coverage: MIRM.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589355362","isCrawlerRequest":true}